Prostate Cancer Daily

June 03, 2026

Videos

Peer-to-Peer Clinical Conversations

CAN-2409 in Localized Prostate Cancer: Protocol, Outcomes, and Patient Perspective - Mark Garzotto & Tom Hulsey

M Garzotto

Mark Garzotto presents updated CAN-2409 data, with Tom Hulsey providing the patient perspective.

PROTEUS Trial: Neoadjuvant Apalutamide and Androgen Deprivation Therapy in High-Risk Localized Prostate Cancer - Mary-Ellen Taplin

Mary-Ellen Taplin

Mary-Ellen Taplin presents PROTEUS trial results.

Beyond the Abstracts

Unveiling the Clinical Potential of Prostate Cancer Three-dimensional Models: A Systematic Review - Beyond the Abstract

Impact of Surgical Waiting List on Oncological Outcomes of Radical Prostatectomy in Patients with Intermediate- and High-Risk Prostate Cancer - Beyond the Abstract

Conference Coverage

SNMMI 2026: Head to Head Comparison of 68Ga-OncoACP3 and 68Ga-PSMA-11 PET for Imaging Prostate Cancer

SNMMI 2026: Longitudinal Outcomes of PSMA PET/CT-Detected Bone Oligometastases: A Two-Center Study

ASCO 2026: Assessment of the Ability of Decipher Prostate Genomic Classifier >0.85 to Identify Patients Who Benefit from Adding Docetaxel to ADT + Enzalutamide: Level 1B Evidence from the ENZAMET Study

ASCO 2026: Practice Patterns and Outcomes by Genomic Risk in Octogenarians with High-Risk Localized Prostate Cancer: A National Real-World Data Analysis

ASCO 2026: Genomic and Transcriptomic Correlates of Deep PSA Response in Patients with mHSPC

Articles

Editor Selected Abstracts and Commentaries

Prostate Cancer

Impact of radiotherapy timing on survival and radiotoxicity outcomes in localized prostate cancer: a retrospective cohort study.

Phase 1b trial of Bavdegalutamide (ARV-110) in combination with Abiraterone for metastatic prostate cancer.

One-year Follow-up after US-guided Transperineal Focal Laser Ablation of Localized Prostate Cancer: Worldwide Registry Study.

Real-World Clinical and Economic Outcomes Among Patients with Localized Prostate Cancer Undergoing Radical Prostatectomy Across Different Risk Stratifications in the United States.

Impact of Absolute PSA Value and Relative PSA Response Rate on Overall Survival in Patients With Metastatic Castration-Sensitive Prostate Cancer Treated With Androgen Receptor Signaling Inhibitors.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2026 Digital Science Press, LLC